启迪药业(000590) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥65,220,251.47, a decrease of 15.40% compared to ¥77,093,552.53 in the same period last year[5]. - The net profit attributable to shareholders was -¥16,256,161.33, representing a decline of 96.23% from -¥8,284,339.28 year-on-year[5]. - The net cash flow from operating activities was -¥53,790,978.90, a decrease of 27.29% compared to -¥42,259,969.07 in Q1 2024[5]. - The weighted average return on equity was -2.75%, down from -1.15% in the previous year, indicating a decline in profitability[5]. - Net profit for the period was -16,261,242.26, compared to -8,266,488.58 in the previous period, indicating a worsening of approximately 96.1%[19]. - The total comprehensive income for the period was -16,261,242.26, compared to -8,266,488.58 in the previous period, indicating a decline of about 96.1%[19]. - Basic and diluted earnings per share were both -0.0679, worsening from -0.0346 in the previous period[19]. Assets and Liabilities - Total assets at the end of Q1 2025 were ¥1,021,909,654.24, an increase of 0.84% from ¥1,013,417,469.23 at the end of the previous year[5]. - Total assets amount to CNY 1,021,909,654.24, compared to CNY 1,013,417,469.23 at the beginning of the period, showing a slight increase of 0.9%[15]. - Total liabilities have increased to CNY 436,937,944.70 from CNY 412,184,517.43, marking an increase of 6.0%[15]. - The company's total equity decreased to CNY 584,971,709.54 from CNY 601,232,951.80, reflecting a decline of 2.7%[15]. Cash Flow - Current cash and cash equivalents amount to CNY 144,948,322.13, down from CNY 177,291,724.42 at the beginning of the period, reflecting a decrease of 18.3%[13]. - Cash flow from operating activities showed a net outflow of -53,790,978.90, compared to -42,259,969.07 in the previous period, reflecting a decline of about 27.5%[20]. - Cash flow from investing activities resulted in a net outflow of -7,841,352.18, worsening from -3,218,482.90 in the previous period[21]. - Cash flow from financing activities generated a net inflow of 31,982,675.01, an increase from 23,890,524.01 in the previous period, showing a growth of approximately 33.5%[21]. - The cash and cash equivalents at the end of the period decreased to 130,939,031.68 from 156,475,757.71, a decline of approximately 16.3%[21]. Research and Development - The company's R&D expenses increased by 32.93% to ¥3,367,126.57 from ¥2,533,019.90 in the same period last year, indicating a focus on innovation[8]. - Research and development expenses increased from 2,533,019.90 to 3,367,126.57, representing a growth of about 33.1%[18]. Receivables and Inventory - The company reported a significant increase in receivables, with notes receivable rising by 46.32% to ¥53,627,059.20, primarily due to an increase in received payments[8]. - Accounts receivable increased to CNY 53,627,059.20 from CNY 36,651,641.32, representing a growth of 46.4%[14]. - Inventory has risen to CNY 133,397,493.87, up from CNY 124,783,406.23, indicating an increase of 6.5%[14]. Borrowings - Short-term borrowings surged by 3875.95% to ¥30,000,000.00, reflecting the company's strategy to secure additional financing[8]. - Short-term borrowings rose significantly to CNY 30,000,000.00 from CNY 754,536.30, indicating a substantial increase[15]. Sales Revenue - The company reported a significant increase in sales revenue from 42,260,219.97 to 93,107,680.11, reflecting a growth of about 54.5%[20]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,676, with the largest shareholder holding 24.47% of the shares[10]. Operating Costs - Total operating costs decreased from 85,671,039.65 to 81,374,066.11, a reduction of approximately 5.0%[18]. Product Development - The company has not disclosed any new product developments or market expansion strategies during the call[12].